Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure cardiac performance in hypertension: A case-control study

Blood Pressure Monitoring

Volumn 5, Issue 3, 2000, Pages 187-193

  Verdecchia, P ^a   Schillaci, G ^a   Reboldi, G P ^a   Sacchi, N ^a   Bruni, B ^a   Benemio, G ^a   Porcellati, C ^a  

^a Dipto di Discipline Cardiovascolari   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Diastolic function; Echocardiography; Enalapril; Hypertension; Losartan; Systolic function

Indexed keywords

DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; URIC ACID;

ARTICLE; BLOOD PRESSURE MONITORING; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL;

EID: 0033846289     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126097-200006000-00008     Document Type: Article

References (39)

1. Angiotensin II receptor antagonists
2. Effects of modulators of the renin-angiotensin-aldosterone system on cough
3. Plasma bradykinin and angio-oedema
4. Ambulatory blood pressure: An independent predictor of prognosis in essential hypertension
5. The prognostic value of ambulatory blood pressure
6. For the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension
7. Reversed circadian blood pressure rhythm is associated with occurrence of both fatal and nonfatal vascular events in NIDDM subjects
8. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension. A prospective study
9. Cardiovascular outcome in white-coat versus sustained mild hypertension: A 10 year follow-up study
10. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study
11. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men
12. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
13. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment
14. Prognostic significance of serial changes in left ventricular mass in essential hypertension
15. Quantitative assessment of day-to-day spontaneous variability in non-invasive ambulatory blood pressure measurements in essential hypertension
16. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
17. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
18. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and the impact of overweight
19. Left ventricular midwall mechanics in systemic arterial hypertension: Myocardial function is depressed in pressure-overload hypertrophy
20. Relation of regional cross-fiber shortening to wall thickening in the intact heart: Three-dimensional strain analysis by NMR tagging
21. Prevalence and determinants of left ventricular diastolic filling abnormalities in an unselected hypertensive population
22. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist Iosartan: Results of a randomised, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring
23. Blood pressure effects of the angiotensin II receptor blocker, Iosartan
24. The antihypertensive efficacy of Iosartan and amlodipine assessed with office and ambulatory blood pressure monitoring
25. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: Multicenter trial
26. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension
27. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
28. Regression of left ventricular hypertrophy with Iosartan potassium therapy in patients with hypertension
29. Effects of an angiotensin II receptor antagonist on urinary albumin excretion, left ventricular mass, and systolic and diastolic blood pressures in essential hypertension
30. Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT(1)-receptor blockade in human hypertension
31. Effects of losartan on hypertension and left ventricular mass: A long-term study
32. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension
33. The Losartan Intervention For End-point reduction (LIFE) in Hypertension study - Rationale, design and methods
34. Relationship between changes in left ventricular mass and in clinic and ambulatory pressure in response to antihypertensive therapy
35. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy
36. Regression of hypertensive left ventricular hypertrophy and left ventricular diastolic function
37. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension
38. Midwall left ventricular mechanics: An independent predictor of cardiovascular risk in arterial hypertension
39. Renal effects of angiotensin II receptor blockade in normotensive subjects